What was the market valuation of the chikungunya vaccine market in 2024?

The market valuation of the chikungunya vaccine market was $15.0 Million in 2024. Read More

What is the projected market valuation for the chikungunya vaccine market by 2035?

The projected market valuation for the chikungunya vaccine market is $42.98 Million by 2035. Read More

What is the expected CAGR for the chikungunya vaccine market during the forecast period 2025 - 2035?

The expected CAGR for the chikungunya vaccine market during the forecast period 2025 - 2035 is 10.04%. Read More

What are the different product technology segments in the chikungunya vaccine market?

The product technology segments include Live-Attenuated Virus Vaccines, Inactivated Viral Vaccines, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates, and Others. Read More

What was the valuation of the Recombinant Viral Vaccines segment in 2024?

The valuation of the Recombinant Viral Vaccines segment was $5.0 Million in 2024. Read More

How does the valuation of Adult vaccines compare to Pediatric vaccines in 2024?

In 2024, the valuation of Adult vaccines was $8.0 Million, significantly higher than the $3.0 Million valuation for Pediatric vaccines. Read More

What distribution channels are utilized in the chikungunya vaccine market?

Distribution channels in the chikungunya vaccine market include Hospital Pharmacies, Retail Pharmacies, and Others. Read More

What was the valuation of Retail Pharmacies in 2024?

The valuation of Retail Pharmacies in 2024 was $9.0 Million. Read More

What is the projected growth trend for the Geriatric segment in the chikungunya vaccine market?

The Geriatric segment is projected to grow from a valuation of $4.0 Million in 2024 to $11.48 Million by 2035. Read More

India Chikungunya Vaccine Market

Q: Which companies are key players in the chikungunya vaccine market?

Key players in the chikungunya vaccine market include Sanofi, Takeda Pharmaceutical Company, Bharat Biotech, GSK, Merck & Co., Pfizer, Novavax, and Valneva SE. Read More

ID: MRFR/Pharma/51607-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026

India Chikungunya Vaccine Market Research Report By Product Technology (Live-Attenuated Virus Vaccines, Inactivated Viral Vaccine, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates, Others), By Age Group (Pediatric, Adult, Geriatric) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

India Chikungunya Vaccine Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)10.04%

2024 Market Size$ 15 Million

2025 Market Size$ 16.51 Million

2035 Market Size$ 42.98 Million

Key Players

Sanofi

Takeda Pharmaceutical Company

Bharat Biotech

GSK

Merck & Co.

Pfizer

Trends

Rising Awareness and Education
Government Initiatives and Support
Advancements in Vaccine Development

Opportunities

Public Health Campaigns
Rising Vector Control Initiatives
Investment in Healthcare Infrastructure

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Product Technology (USD Million)
  1. 4.1.1 Live-Attenuated Virus Vaccines
  2. 4.1.2 Inactivated Viral Vaccines
  3. 4.1.3 Recombinant Viral Vaccines
  4. 4.1.4 Chimeric-Alphavirus Candidates
  5. 4.1.5 Others
2. 4.2 Chemicals and Materials, BY Age Group (USD Million)
  1. 4.2.1 Pediatric
  2. 4.2.2 Adult
  3. 4.2.3 Geriatric
3. 4.3 Chemicals and Materials, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Sanofi (FR)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Takeda Pharmaceutical Company (JP)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bharat Biotech (IN)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GSK (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novavax (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Valneva SE (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY PRODUCT TECHNOLOGY
3. 6.3 INDIA MARKET ANALYSIS BY AGE GROUP
4. 6.4 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
11. 6.11 CHEMICALS AND MATERIALS, BY PRODUCT TECHNOLOGY, 2024 (% SHARE)
12. 6.12 CHEMICALS AND MATERIALS, BY PRODUCT TECHNOLOGY, 2024 TO 2035 (USD Million)
13. 6.13 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT TECHNOLOGY, 2025-2035 (USD Million)
  2. 7.2.2 BY AGE GROUP, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

India Chikungunya Vaccine Market Segmentation

India Chikungunya Vaccine Market By Product Technology (USD Million, 2025-2035)

Live-Attenuated Virus Vaccines
Inactivated Viral Vaccines
Recombinant Viral Vaccines
Chimeric-Alphavirus Candidates
Others

India Chikungunya Vaccine Market By Age Group (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

India Chikungunya Vaccine Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Others

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”